Core Viewpoint - Elutia Inc. is set to release its fourth quarter and full year 2024 financial results on March 6, 2025, with a conference call scheduled for the same day [1]. Company Overview - Elutia specializes in developing and commercializing drug-eluting biomatrix products aimed at enhancing the compatibility of medical devices with patients [3]. - The company is focused on addressing the needs of a growing population requiring implantable technologies, with a mission to humanize medicine for better patient outcomes [3]. Conference Call Details - The conference call will begin at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on March 6, 2025 [1]. - Access information for the call includes a U.S. investor line at 877-407-8029 and an international line at 201-689-8029, with a Conference ID of 13751810 [2]. - A live and archived webcast will be available on the "Investors" section of Elutia's website [2].

Core Viewpoint - Elutia Inc. has announced a definitive agreement for a registered direct offering of shares and prefunded warrants, aiming to raise approximately $15.0 million in gross proceeds [1][2]. Group 1: Offering Details - The company will sell 5,520,000 shares of Class A common stock at a price of $2.50 per share [1]. - Additionally, 480,000 prefunded warrants will be sold at a price of $2.499 each, which are immediately exercisable at an exercise price of $0.001 [1]. - The offering is expected to close on or about February 4, 2025, subject to customary closing conditions [1]. Group 2: Use of Proceeds - Elutia intends to utilize the proceeds from the offering for working capital and other general corporate purposes [2]. Group 3: Regulatory Information - The securities are being offered under an effective shelf registration statement on Form S-3, previously filed with the SEC [3]. - The offering will be made only by means of a prospectus supplement that is part of the registration statement [3].

Core Insights - Elutia Inc. has launched EluPro™, the first FDA-cleared antibiotic-eluting biomatrix for use with cardiac implantable electronic devices (CIEDs) and neurostimulators, marking a significant innovation in the medical device industry [1][2][3] Company Overview - Elutia focuses on developing drug-eluting biomatrix products aimed at improving compatibility between medical devices and patients, with a mission to humanize medicine [5] Product Launch Details - The launch of EluPro follows a successful pilot program that demonstrated strong physician adoption and positive patient outcomes, with orders increasing over 50% post-approval by hospital value analysis committees [2][3] - EluPro combines antibiotics rifampin and minocycline with a regenerative biomatrix, addressing infection prevention and promoting healing, which is critical given the 5-7% complication rates associated with CIEDs [3] Market Context - Over 600,000 CIEDs are implanted annually in the U.S., with a market value of $600 million for CIED protection, highlighting the potential for EluPro to capture significant market share [3]

Core Insights - Elutia Inc. has entered into an agreement with Vizient to provide access to its EluPro Antibiotic Eluting BioEnvelope to Southern Strategic Sourcing Partners (S3P), which includes 993 acute care facilities [1][3] - EluPro is the first antibiotic-eluting biologic envelope approved by the FDA for use with cardiac implantable electronic devices and neurostimulators, addressing post-surgical challenges such as infection and skin erosion [2] - The partnership with S3P is a significant milestone for Elutia, marking its second major group purchasing organization (GPO) partnership ahead of EluPro's full commercial launch [3] Company Overview - Elutia develops drug-eluting biomatrix products aimed at improving compatibility between medical devices and patients, with a mission to humanize medicine [4] - The company is focused on addressing the needs of a growing population requiring implantable technologies [4]

Group 1 - Elutia Inc. (ELUT) is a notable stock in the Medical sector, currently outperforming its peers with a year-to-date gain of 83.3% compared to an average loss of 1.7% in the Medical group [4] - The Medical group consists of 1022 companies and holds a Zacks Sector Rank of 3, indicating strong performance relative to other sectors [2] - Elutia Inc. has a Zacks Rank of 2 (Buy), with its full-year earnings estimate increasing by 42.5% in the past quarter, reflecting improved analyst sentiment [3] Group 2 - Elutia Inc. is part of the Medical - Biomedical and Genetics industry, which includes 502 companies and currently ranks 67 in the Zacks Industry Rank, with the industry experiencing an average loss of 8.8% this year [6] - Adma Biologics (ADMA) is another stock in the Medical sector that has significantly outperformed, with a year-to-date return of 313.1% [4] - Investors should closely monitor Elutia Inc. and Adma Biologics for potential continued strong performance in the Medical sector [7]

3rd Quarter 2024 Financial Results Call C. Randal Mills PhD Chief Executive Officer Matt Ferguson Chief Financial Officer November 14, 2024 Forward-Looking Statements This presentation of Elutia Inc. ("Elutia," "we," "us," "our" or the "Company") (together with any other statements or information that we may make or discuss in connection herewith) contains forward-looking statements. All statements other than statements of historical facts, including but not limited to statements regarding the launch of Elu ...

Financial Data and Key Metrics Changes - Elutia reported financial results for the quarter ended September 30, 2024, with specific metrics available in the press release [2]. Business Line Data and Key Metrics Changes - Detailed performance metrics for each business line were not provided in the available content. Market Data and Key Metrics Changes - Specific market data and key metrics were not disclosed in the available content. Company Strategy and Development Direction and Industry Competition - The management emphasized the importance of forward-looking statements regarding operating trends and future financial performance, indicating a strategic focus on growth and adaptation to market conditions [3][4]. Management Comments on Operating Environment and Future Outlook - Management highlighted that forward-looking statements involve material risks and uncertainties, suggesting a cautious approach to future expectations [4][5]. Other Important Information - The company provided a reminder about the risks associated with its business, referencing the Risk Factors section of its public filings with the SEC [5]. Q&A Session All Questions and Answers - No specific questions and answers from the Q&A session were included in the available content.

Table of Contents (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period ...

Exhibit 99.1 Elutia Announces Strong Third Quarter Results, Accelerating Toward Full Launch of EluPro Antibiotic-Eluting BioEnvelope in 2025 Over 100 EluPro VAC Submissions and 19% SimpliDerm Growth Drive Momentum into 2025 SILVER SPRING, Md., November 14, 2024 — Elutia Inc. (Nasdaq: ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix products, today provided a business update and financial results for the third quarter ended September 30, 2024. Business Highlights: · First Commercial Use ...

SILVER SPRING, Md., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) ("Elutia"), a leader in drug-eluting biomatrix products, today announced that Dr. Randy Mills, President and Chief Executive Officer, will present at the LD Micro Main Event XVII Conference in Los Angeles on Wednesday, October 30, 2024, at 2:00 p.m. PT (5:00 p.m. ET). LD Micro Main Event XVII Conference Presentation Date: Wednesday, October 30, 2024 Presentation Time: 2:00 p.m. PT (5:00 p.m. ET) Webcast: Click here Elutia manag ...